Join us in Asia’s premier CBRNe event – The Non-Conventional Threat: CBRNe Asia Pacific 2018 that will take place 28-30 May in Tokyo, Japan. Look out for us to find out more about how we can help you in bio-surveillance.
Veredus Laboratories Pte Ltd is pleased to announce its acquisition by SEKISUI CHEMICAL CO., LTD1.
Founded in 2003, Veredus Laboratories Pte Ltd (hereinafter, “Veredus”) specializes in the development, manufacturing and marketing of innovative multiplexed molecular solutions in the clinical, specialty, and custom testing markets based on STMicroelectronics’ Lab-on-Chip platform. The Lab-on-Chip platform, also known as the VerePLEX™ Biosystem, combines Micro-Electro Mechanical Systems (MEMS) with micro-fluidics to integrate multiplexed DNA amplification with microarray detection for rapid, cost-effective, and accurate analysis of biological materials.
With this acquisition, Veredus will continue to carry its own product line and also welcome the medical products from SEKISUI MEDICAL CO., LTD., a company which is 100% subsidiary of SEKISUI CHEMICAL CO., LTD.
Dr Rosemary Tan will continue to lead Veredus as its Chief Executive Officer, and Veredus remains fully committed in bringing innovative technologies and quality products to our customers.
1Refer to Official Press Release by SEKISUI CHEMICAL CO., LTD, dated 3rd April, 2018
Clinica Medtech Intelligence is the leading provider of business-critical intelligence for the global medical technology industry. Its content offering includes news and analysis on global policy and regulatory developments, competitor intelligence and market insight.
Read more about Veredus Laboratories from the article titled “From robotics to diagnostics: Singapore spreads its innovation wings” written by Clinica Medtech Intelligence.